Abpro Holdings, Inc. (ABPWW)

Abpro Holdings, Inc. makes engineered antibodies — proteins that the immune system uses to recognize and attack disease. The company designs antibodies that do something natural antibodies don’t: they hit two targets at once, or combine different antibody shapes for a stronger effect. The company’s common stock trades as ABP; the warrants trade as ABPWW on the Nasdaq Capital Market. Abpro was incorporated in 2004 and is based in Woburn, Massachusetts.

What antibodies are and why you might engineer them

Your immune system makes antibodies naturally. When you get infected or vaccinated, your B cells learn to spot the invader and produce proteins called antibodies that lock onto specific spots on viruses or bacteria. Once locked on, these antibodies mark the intruder for destruction by other immune cells.

Pharmaceutical companies have learned to make antibodies in the lab. A drug made from an antibody is actually just a copy of a natural immune protein — manufactured in big bioreactors instead of in your bloodstream. Antibodies are good at recognizing specific disease targets, which makes them useful drugs. Many cancers, autoimmune diseases, and infections are now treated with monoclonal antibodies — drugs where all the antibody molecules are identical copies of one specific antibody.

Abpro’s core insight is simpler: single antibodies are good, but what if you engineered them to do more than one thing? The company has two main technology platforms.

The two technology platforms

DiversImmune is Abpro’s antibody discovery system. It generates large collections of different antibodies against targets the company chooses. Instead of trying to discover the best antibody for one target through screening, the company builds diversity by design, generating many antibodies quickly and testing them to find the most effective ones. This is useful because it speeds up the hunt for good starting antibodies against new disease targets.

MultiMab is the more distinctive platform. It lets Abpro’s engineers take two or more antibody fragments and assemble them into novel constructs — antibodies that simultaneously attack two different targets. This is harder than it sounds. Natural antibodies have a fixed shape that works well for doing one job. Engineering them to do two jobs at once requires completely rethinking their structure while keeping them stable, soluble, and able to reach their targets in a living organism.

The pipeline — what they’re actually developing

Abpro’s lead candidate is ABP-102, a dual-targeting antibody hitting HER2 and CD3. HER2 is a protein often overexpressed on cancer cells in breast and gastric tumors. CD3 is a surface marker on immune cells called T cells. By hitting both, ABP-102 pulls T cells directly to the cancer cells — essentially wiring the immune system to attack. This approach, called bispecific antibody therapy, is becoming common in oncology, but engineering a version that works well in the body is still difficult.

ABP-201 targets VEGF and ANG-2 — two proteins involved in blood vessel formation. In eye diseases like wet macular degeneration and diabetic retinopathy, abnormal blood vessel growth damages vision. Blocking both pathways at once may offer better control than blocking either alone. This is developed specifically for diseases of the eye.

ABP-110 targets GPC3 and CD3, aimed at hepatocellular carcinoma — liver cancer. GPC3 is often overexpressed in liver cancer, making it a recognizable target for immune cells.

ABP-150 targets claudin 18.2 and CD3, aimed at gastric cancer. Claudin 18.2 is a protein on the surface of stomach cancer cells that distinguishes them from healthy stomach lining — a useful feature for an antibody that needs to spare healthy tissue.

How the company makes money (or doesn’t yet)

Abpro doesn’t sell drugs to patients. Its pipeline molecules are still in development. The company is likely funded through equity investment from venture capital and institutional investors. Revenue might eventually come from licenses to larger pharmaceutical companies — a smaller biotech with promising candidates often partners with a bigger pharma that has the capital and infrastructure to run late-stage trials and sell the drug if approved. Alternatively, if Abpro’s science proves out, a larger company could buy the entire firm.

Why this approach matters

Bispecific antibodies have become a real category in oncology and immunology. Companies like Genmab and Janssen have already brought dual-targeting antibodies to market. Abpro’s platform approaches this through engineering — designing antibodies with new structures rather than just combining existing natural antibodies. The advantage is specificity and control; the disadvantage is that engineering adds complexity, and complexity sometimes means the drug doesn’t work as predicted when tested in humans.

The investors and the warrants

The warrant ticker ABPWW reflects how many biotech companies raise capital. Investors who bought the original units received both shares and warrants — options to buy more shares at a set price. Warrants amplify gains and losses compared to common stock. They are riskier investments than the common shares themselves.

Research and due diligence

Anyone interested in Abpro should read the company’s SEC filings using CIK 0001893219. Look for clinical updates on the lead programs, cash position, and burn rate — how fast the company is spending money. Biotech investors should also track whether the company secures partnerships or additional funding, which would extend the runway and reduce the risk of running out of cash before the science pays off. The real signal comes from clinical trial data: do the engineered antibodies actually work better than simpler alternatives in real patients? Until that question is answered, the company remains speculative.